|
Cholangiocarcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
CDK7 inhibitor THZ1 inhibits MCL1 synthesis and drives cholangiocarcinoma apoptosis in combination with BCL2/BCL-XL inhibitor ABT-263.
|
31399555 |
2019 |
|
Cholangiocarcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Actinidia arguta (Hardy Kiwi) Root Extract Exerts Anti-cancer Effects via Mcl-1-Mediated Apoptosis in Cholangiocarcinoma.
|
30633583 |
2019 |
|
Cholangiocarcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, we found that both SPHK2 and MCL1 protein expression were significantly higher in cholangiocarcinoma than that in nontumoral bile ducts.
|
30949409 |
2019 |
|
Cholangiocarcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Fibroblast growth factor receptor inhibition induces loss of matrix MCL1 and necrosis in cholangiocarcinoma.
|
29408314 |
2018 |
|
Cholangiocarcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We also showed that the two FBXW7 substrates, NOTCH1 and myeloid cell leukemia sequence 1 (MCL1), regulate cholangiocarcinoma progression.
|
30302867 |
2018 |
|
Cholangiocarcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
LIFR silencing and Mcl-1 blockade restored drug-induced apoptosis.In conclusion, autocrine and paracrine LIF signaling promote chemoresistance in cholangiocarcinoma by up-regulating Mcl-1 via a novel STAT3- and MAPK-independent, PI3K/AKT-dependent pathway.
|
26296968 |
2015 |
|
Cholangiocarcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Interleukin 6 (IL-6)-mediated signal transducers and activators of transcription 3 (STAT-3) phosphorylation (activation) is aberrantly sustained in cholangiocarcinoma cells resulting in enhanced myeloid cell leukemia 1 (Mcl-1) expression and resistance to apoptosis.
|
25344679 |
2014 |
|
Cholangiocarcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Two selected miRNAs, mir-204 and mir-320, were introduced into cholangiocarcinoma cell lines to examine their effects on potential target genes, Bcl-2 and Mcl-1, respectively.
|
19070389 |
2009 |
|
Cholangiocarcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
SOCS-3 epigenetic silencing is responsible for sustained IL-6/STAT-3 signaling and enhanced Mcl-1 expression in cholangiocarcinoma.
|
17241887 |
2007 |
|
Cholangiocarcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We conclude that modulation of IL-6 mediated survival signaling pathways involving the p38 MAPK or downstream targets such as Mcl-1 may prove useful therapeutic strategies for human cholangiocarcinoma.
|
16469407 |
2006 |
|
Cholangiocarcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We examined this cascade in IL-6 regulation of Mcl-1 transcription in human cholangiocarcinoma cell lines.
|
16317687 |
2005 |
|
Cholangiocarcinoma
|
0.100 |
AlteredExpression
|
disease |
LHGDN |
Immunohistochemistry showed that the serine/threonine kinase Akt and Mcl-1 are strongly expressed in the preneoplastic bile duct inflammatory disease primary sclerosing cholangitis and in human cholangiocarcinoma specimens.
|
15940637 |
2005 |
|
Cholangiocarcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Immunohistochemistry showed that the serine/threonine kinase Akt and Mcl-1 are strongly expressed in the preneoplastic bile duct inflammatory disease primary sclerosing cholangitis and in human cholangiocarcinoma specimens.
|
15940637 |
2005 |
|
Cholangiocarcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, these studies not only demonstrate that Mcl-1 mediates TRAIL resistance in cholangiocarcinoma cells by blocking the mitochondrial pathway of cell death but also identify two strategies for circumventing this resistance.
|
15150106 |
2004 |
|
Cholangiocarcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Overexpression of Mcl-1, a potent antiapoptotic protein of the Bcl-2 family, has also been reported in cholangiocarcinomas.
|
12438243 |
2002 |